Gulam A. Manji, MD, PhD
Appointments
Phone Appointments
Connect Patient Portal
For existing patients, login to make an appointment, view documentation or contact your care provider.
Credentials & Experience
Board Certifications
- Internal Medicine
- Medical Oncology
Clinical Expertise
- Clinical Research Trials
- Gallbladder Cancer
- Gastrointestinal Malignancies
- Gastrointestinal Malignancy
- Liver Lesions
- Liver Masses
- Liver Tumors
- Pancreas Cancer
- Pancreas Cyst
- Pancreatic Cysts
- Pancreatic Tumor
- Sarcoma
Specialties
Education & Training
- Ross University School of Medicine
- University of Wisconsin
- Residency: Albany Medical Center
- Fellowship: NewYork-Presbyterian Hospital/Columbia University Medical Center
About Gulam Manji
Gulam Manji, M.D., Ph.D. is an Assistant Professor of Medicine at Columbia University Medical Center. Dr. Manji received his M.D. degree from Ross University School of Medicine in 2009 and completed his residency in internal medicine at Albany Medical College. He then completed his fellowship in Hematology/Oncology at NewYork-Presbyterian/Columbia, where his clinical focus was on the treatment of gastrointestinal malignancies, melanoma, and sarcoma under the mentorship of Dr. Gary Schwartz, Chief of Hematology and Oncology.
Dr. Manji conducts translational research with the overall goal to developing new treatments for cancer. His focus is in gastrointestinal malignancies, particularly pancreas adenocarcinoma, on which he is conducting preclinical combination immunotherapy studies on genetically engineered mice with pancreas cancer in the Olive laboratory at the Herbert Irving Comprehensive Cancer Center. The combination immunotherapy preclinical proposal received the Young Investigator Award from the American Society of Clinical Oncology-2015. The goal of these preclinical studies is to bring promising new therapies to the clinic in an early phase clinical trials Dr. Manji's research career in identifying new genes and their implication in disease has led to numerous key publications and an issued patent.
Dr. Manji cares for patients with gastrointestinal malignancies, with a particular focus on pancreatic and liver cancers, and sarcomas. He is the principal investigator of an investigator-initiated multicenter clinical trial that he wrote with Dr. Gary Schwartz in sarcoma and malignant peripheral nerve sheath tumors and is responsible for clinical trials conducted in liver, bile duct, gallbladder, and pancreas cancers at Columbia University Medical Center.
Academic Titles
- Assistant Professor of Medicine at CUMC
Administrative Positions
- Director of Medical Oncology and Translational Research for The Pancreas Center
Gender
- Male
Insurance Accepted
Aetna
- EPO
- HMO
- Medicare Managed Care
- NYP Employee Plan
- NY Signature
- POS
- PPO
- Signature Administrators
- Student Health
Affinity
- Essential Plan
- Medicaid Managed Care
AgeWell
- Medicare Managed Care
- Special Needs Plan
Amida Care
- Special Needs Plan
Capital District Physician Health Plan
- Capital District Physician Health Plan
Cigna
- EPO
- Great West
- HMO
- POS
- PPO
Emblem/GHI
- Medicare Managed Care
- PPO
Emblem/HIP
- ConnectiCare
- EPO
- Essential Plan
- HMO
- Medicaid Managed Care
- Medicare Managed Care
- POS
- PPO
- Select Care (Exchange)
- Vytra
Empire Blue Cross Blue Shield
- EPO
- Medicare Managed Care
- PPO
Empire Blue Cross Blue Shield HealthPlus
- Child/Family Health Plus
- Essential Plan
- Medicaid Managed Care
Fidelis Care
- Child/Family Health Plus
- Medicaid Managed Care
- Medicare Managed Care
Healthfirst
- Child/Family Health Plus
- Leaf (Exchange)
- Medicaid Managed Care
- Medicare Managed Care
Local 1199
- Local 1199
MagnaCare
- MagnaCare
Multiplan
- Multiplan
MVP Health Care
- Child/Family Health Plus
- Essential Plan
- HMO
- Medicaid Managed Care
Oxford Health Plans
- Freedom
- Liberty
UnitedHealthcare
- Columbia University Employee Plan
- Compass (Exchange)
- HMO
- Medicaid (Community Plan)
- Medicare Managed Care
- POS
- PPO
VNSNY CHOICE
- Medicare Managed Care
- SelectHealth
- Special Needs Plan
WellCare
- Medicaid Managed Care
- Medicare Managed Care
*Please contact the provider’s office directly to verify that your particular insurance is accepted.
Contact & Locations
Research
Grants
MEKIAUTO:PHASE 1/2 OPEN-LABEL STUDY OF COMBINATION THERAPY WITH THE MEK INHIBITOR, COBIMETINIB, IMMUNE CHECKPOINT BLOCKADE, ATEZOLIZUMAB, AND THE AUTOPHAGY INHIBITOR, HYDROXYCHLOROQUINE IN KRAS-MUTATED ADVANCED MALIGNANCIES. (P&S Industry Clinical Trial)
Jan 31 2020 - Jan 31 2025
A PHASE 1 STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF AB680 COMBINATION THERAPY IN PARTICIPANTS WITH GASTROINTESTINAL MALIGNANCIES (P&S Industry Clinical Trial)
Jan 17 2020 - Jan 17 2025
APHASE 1/2 STUDY OF GRT-C903/GRT-R904, A VACCINE TARGETING SHARED NEOANTIGENS, IN COMBINATION WITH IMMUNE CHECKPOINT BLOCKADE FOR PATIENTS WITH ADVANCED SOLID TUMORS (P&S Industry Clinical Trial)
Sep 10 2019 - Sep 10 2024
A PHASE I/II OPEN LABEL STUDY TO INVESTGATE THE SAFETY CLINICAL ACTIVITY PHARMACOKINETICS AND PHARMACODYNAMICS OD GSK 3145095 ADMINSTERED ALONE AND IN COMBO WITH ANNTICANCER AGENTS INCLUDING PEMBROLIZUMAB IN ADULT PARTIPANTS WITH SELECTED ADVANCED SOLID (P&S Industry Clinical Trial)
Apr 29 2019 - Apr 29 2024
APHASE 1/2 FEASIBILITY, SAFETY, AND ACTIVITY STUDY OF PSCA-SPECIFIC CHIMERIC ANTIGEN RECEPTOR ENGINEERED T CELLS (BPX-601) IN SUBJECTS WITH PREVIOUSLY TREATED ADVANCED SOLID TUMORS (P&S Industry Clinical Trial)
Apr 11 2019 - Apr 11 2024
APHASE IB, MULTICENTER, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF CIBISATAMAB IN COMBINATION WITH ATEZOLIZUMAB AFTER PRETREATMENT (P&S Industry Clinical Trial)
Mar 7 2019 - Mar 7 2024
APHASE IB/II, OPEN-LABEL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFTEY OF MULTIPLE IMMUNOTHERAPY-BASED TREATMENT COMBINATIONS IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL (P&S Industry Clinical Trial)
Sep 22 2017 - Sep 22 2022
APHASE IB/II, OPEN LABEL, MULTICENTER, RANDOMIZED, UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MULTIPLE IMMUNOTHERAPY BASED TREATMENT COMBINATINOS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MORPHEUS - PANCREATIC CANCER) (P&S Industry Clinical Trial)
Jun 9 2017 - Jun 9 2022
ANOPEN-LABEL, MULTICENTER, DOSE-ESCALATION PHASE I STUDY TO EVALUATE THE SAFETY, NOEMBRYONIC ANTIGEN (CEA) ON TUMOR CELLS AND CD3 ON T-CELLS, ADMINISTERED INTRAVENOUSLY IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC CEA(+) SOLID TUMORS (P&S Industry Clinical Trial)
Apr 26 2017 - Apr 26 2022
ANOPEN-LABEL, MULTICENTER, DOSE ESCALATION AND EXPANSION PHASE IB STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF RO6958688 IN COMBINATION WITH TEZOLIZUMAB IN PATIENTS WITH LOCALLY (P&S Industry Clinical Trial)
Mar 8 2017 - Mar 8 2022
PHASE 2 STUDY OF COMBINATION THERAPY WITH PLX3397 AND SIROLIMUS TO TARGET TUMOR-ASSOCIATED MACROPHAGES IN MALIGNANT PERIPHERAL NERVE SHEATH TUMORS (Federal Gov)
Mar 5 2017 - Feb 28 2021
A PHASE II STUDY OF CHEMOTHERAPY AND IMMUNE CHECKPOINT BLOCKADE WITH PEMBROLIZUMAB IN THE PERIOPERATIVE AND MAINTENANCE TREATMENT OF LOCOREGIONAL GASTRIC OR GE JUNCTION ADENOCARCINOMA (P&S Industry Clinical Trial)
Jan 12 2017 - Jan 12 2021
ARANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY OF MM-141 PLUS NAB-PACLITAXEL AND GEMCITABINE VERSUS NAB-PACLITAXEL AND GEMCITABINE IN FRONT-LINE METASTATIC PANCREATIC CANCER (CARRIE) (P&S Industry Clinical Trial)
Nov 24 2015 - Nov 24 2020
A PHASE II CLINICAL TRIAL OF PEMBROLIZUMAB AS MONOTHERAPY AND IN COMBINATION WITH CISPLATIN+5-FLUOROURACIL IN SUBJECTS WITH RECURRENT OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (KEYNOTE-059) (P&S Industry Clinical Trial)
Aug 27 2015 - Aug 27 2020
A DOSE ESCALATION AND COHORT EXPANSION STUDY OF DKN-01 IN COMBINATION WITH GEMCITABINE AND CISPLATIN IN PATIENTS WITH ADVANCED CARCINOMA PRIMARY TO THE INTRA- OR EXTRA-HEPATIC BILIARY SYSTEM OR GALLBLADDER (P&S Industry Clinical Trial)
Mar 31 2015 - Mar 31 2020
APHASE 1B/2 STUDY OF MEDI4736 IN COMBINATION WITH TREMELIMUMAB, MEDI4736 MONOTHERAPY, AND TREMELIMUMAB MONOTHERAPY IN SUBJECTS WITH METASTATIC OR RECURRENT GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA (P&S Industry Clinical Trial)
Mar 23 2015 - Mar 23 2020
PRECLINICAL EVALUATION OF COMBINATION IMMUNOTHERAPY APPROACHES FOR PANCREATIC DUCTAL ADENOCARCINOMA (Private)
Jul 1 2015 - Jun 30 2016